In the early nineteenth century the major economic players of the Atlantic trade lanes -- the United States, Brazil, and Cuba -- witnessed explosive commercial growth. Commodities like cotton, coffee, and sugar contributed to the fantastic wealth of an elite few and the enslavement of many. As a result of an increased population and concurrent economic expansion, the United States widened its trade relationship with Cuba and Brazil, importing half of Brazil's coffee exports and 82 percent of Cuba's total exports by 1877. Disease, Resistance, and Lies examines the impact of these burgeoning markets on the Atlantic slave trade between these countries from 1808 -- when the U.S. government outlawed American involvement in the slave trade to Cuba and Brazil -- to 1867, when slave traffic to Cuba ceased. In his comparative study, Dale Graden engages several important historiographic debates, including the extent to which U.S. merchants and capital facilitated the slave trade to Brazil and Cuba, the role of infectious disease in ending the trade to those countries, and the effect of slave revolts in helping to bring the transatlantic slave trade to an end. Graden situates the transatlantic slave trade within the expanding and rapidly changing international economy of the first half of the nineteenth century, offering a fresh analysis of the "Southern Triangle Trade" that linked Cuba, Brazil, and Africa. Disease, Resistance, and Lies challenges more conservative interpretations of the waning decades of the transatlantic slave trade by arguing that the threats of infectious disease and slave resistance both influenced policymakers to suppress slave traffic to Brazil and Cuba and also made American merchants increasingly unwilling to risk their capital in the transport of slaves.

Disease resistance is one of the major factors that can be improved to sustain yield potential in cultivated crops. This book looks at disease resistance in wheat, concentrating on all the economically important diseases -- their economic impact and geographical spread, breeding for resistance, pathogen variability, resistance mechanisms and recent advances made on resistance genes. Newer strategies for identifying resistance genes and identify resistance mechanisms are discussed, including cloning, gene transfer and the use of genetically modified plants.

Plant resistance to pathogens is one of the most important strategies of disease control. Knowledge of resistance mechanisms, and of how to exploit them, has made a significant contribution to agricultural productivity. However, the continuous evolution of new variants of pathogen, ana additional control problems posed by new crops and agricultural methods, creates a need for a corresponding increase in our understanding of resistance and ability to utilize it. The study of resistance mechanisms also has attractions from a purely academic point of view. First there is the breadth of the problem, which can be approached at the genetical, molecular, cellular, whole plant or population lev~ls. Often there is the possibility of productive exchange of ideas between different disciplines. Then there is the fact that despite recent advances, many of the mechanisms involved have still to be fully elucidated. Finally, and compared with workers in other areas of biology, the student of resistance is twice blessed in having as his subject the interaction of two or more organisms, with the intriguing problems of recognition, specificity and co-evolution which this raises.

A scientist reveals the groundbreaking evidence linking many major diseases, including cancer, diabetes, and Alzheimer's disease, to a common root cause—insulin resistance—and shares an easy, effective plan to reverse and prevent it. We are sick. Around the world, we struggle with diseases that were once considered rare. Cancer, heart disease, Alzheimer's disease, and diabetes affect millions each year; many people are also struggling with hypertension, weight gain, fatty liver, dementia, low testosterone, menstrual irregularities and infertility, and more. We treat the symptoms, not realizing that all of these diseases and disorders have something in common. Each of them is caused or made worse by a condition known as insulin resistance. And you might have it. Odds are you do—over half of all adults in the United States are insulin resistant, with most other countries either worse or not far behind. In Why We Get Sick, internationally renowned scientist and pathophysiology professor Benjamin Bikman explores why insulin resistance has become so prevalent and why it matters. Unless we recognize it and take steps to reverse the trend, major chronic diseases will be even more widespread. But reversing insulin resistance is possible, and Bikman offers an evidence-based plan to stop and prevent it, with helpful food lists, meal suggestions, easy exercise principles, and more. Full of surprising research and practical advice, Why We Get Sick will help you to take control of your health.

Drug-resistant bacteria — known as superbugs — are one of the biggest medical threats of our time. Here, a doctor, researcher, and ethics professor tells the exhilarating story of his race to beat them and save countless lives. When doctor Matt McCarthy first meets Jackson, a mechanic from Queens, it is in the ER, where he has come for treatment for an infected gunshot wound. Usually, antibiotics would be prescribed, but Jackson’s infection is one of a growing number of superbugs, bacteria that have built up resistance to known drugs. He only has one option, and if that doesn’t work he may lose his leg or even his life. On the same day, McCarthy and his mentor Tom Walsh begin work on a groundbreaking clinical trial for a new antibiotic they believe will eradicate certain kinds of superbugs and demonstrate to Big Pharma that investment in these drugs can save millions of lives and prove financially viable. But there are countless hoops to jump through before they can begin administering the drug to patients, and for people like Jackson time is in short supply. Superbugs is a compelling tale of medical ingenuity. From the muddy trenches of the First World War, where Alexander Fleming searched for a cure for soldiers with infected wounds, to breakthroughs in antibiotics and antifungals today that could revolutionise how infections are treated, McCarthy takes the reader on a roller-coaster ride through the history — and future — of medicine. Along the way, we meet patients like Remy, a teenage girl with a dangerous and rare infection; Donny, a retired firefighter with a compromised immune system; and Bill, the author’s own father-in-law, who contracts a deadly staph infection. And we learn about the ethics of medical research: why potentially life-saving treatments are often delayed for years to protect patients from exploitation. Can McCarthy get his trial approved and underway in time to save the lives of his countless patients infected with deadly bacteria, who have otherwise lost all hope?

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

The political and religious forces which led to the decline of the slave trade in nineteenth century Bahia, Brazil.